VGLL4 anticorps (AA 220-270) (FITC)

N° du produit ABIN1401332

Détail du produit anti-VGLL4 anticorps (FITC)

Antigène: VGLL4 (Vestigial Like 4 (VGLL4))

Épitope: AA 220-270

Reactivité: Humain, Souris, Rat

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp VGLL4 est conjugé à/à la FITC

Application: Western Blotting (WB), Immunofluorescence (Paraffin-embedded Sections) (IF (p))

Réactivité croisée: Humain, Souris, Rat

Purification: Purified by Protein A.

Immunogène: KLH conjugated synthetic peptide derived from human VGLL4

Isotype: IgG

Information d'application

Indications d'application: IF(IHC-P) 1:50-200

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Date de péremption: 12 months

Détails sur VGLL4

Antigène: VGLL4 (Vestigial Like 4 (VGLL4))

Autre désignation: VGLL4 (VGLL4 Produits)

Synonymes: anticorps DKFZp459C0333, anticorps VGL-4, anticorps BC048841, anticorps vestigial-like family member 4, anticorps vestigial like family member 4, anticorps Vgll4, anticorps VGLL4

Sujet:

Synonyms: Transcription cofactor vestigial like protein 4, Vestigial like protein 4, VGL 4, VGLL4, VGLL4_HUMAN.

Background: The transcriptional enhancer factor-1 (TEF-1) family of transcription factors regulate tissue-specific gene expression in muscle and placenta. The mechanism whereby TEF-1 confers tissue specificity depends largely on the interaction of TEF-1 with tissue-specific cofactors. Transcription cofactor Vgl-4 (vestigial-like protein 4) is a 290 amino acid nuclear protein that interacts with TEF-1 and MEF-2. Vgl-4 is the only member of the vestigial-like family that is expressed in heart. Overexpression of Vgl-4 in cardiac myocytes interferes with basal expression and ?-adrenergic receptor-dependent activation of a TEF-1 dependent skeletal ?actin promoter. This suggests that Vgl-4 counteracts ?-adrenergic activation of gene expression in cardiomyocytes. There are two isoforms of Vgl-4 that are produced as a result of alternative splicing events.

ID gène: 9686

UniProt: Q14135